Cordis

The Cordish Companies Launches New PlayLive! Internet Gaming Website in Pennsylvania

Retrieved on: 
Monday, August 17, 2020
The Cordish Companies, Cordis, Economy of the United States, Reed Cordish

HANOVER, Md., Aug. 17, 2020 /PRNewswire/ --Cordish Gaming Group, a division of The Cordish Companies, today announced the launch of PlayLive!, their new branded Internet gambling business in the Commonwealth of Pennsylvania.

Key Points: 
  • HANOVER, Md., Aug. 17, 2020 /PRNewswire/ --Cordish Gaming Group, a division of The Cordish Companies, today announced the launch of PlayLive!, their new branded Internet gambling business in the Commonwealth of Pennsylvania.
  • Casinos & Hotels are owned and operated by companies that are affiliated with world-renowned developers The Cordish Companies.
  • The Cordish Companies has developed and operates highly acclaimed dining, entertainment and hospitality destinations throughout the United States, many falling under The Cordish Companies' Live!
  • "The Cordish Companies," "The Cordish Company" and "Cordish" are trademarks used under license by independent corporations, legal liability companies and partnerships ("Cordish Entities").

MedAlliance Gains CE Mark Approval for Coronary SELUTION SLR™ Sirolimus Drug Eluting Balloon

Retrieved on: 
Tuesday, June 30, 2020
Medicine, Interventional cardiology, Medical technology, Clinical medicine, Peripheral artery disease, RTT, Artery disease, Cordis, Drug-eluting stent, Medical devices, Interventional radiology

NYON, Switzerland, June 30, 2020 /PRNewswire/ -- MedAlliance has announced the award of its second CE Mark: SELUTION SLR 014 PTCA, a novel Sirolimus Drug Eluting Balloon (DEB), for the treatment of coronary arterial disease.

Key Points: 
  • NYON, Switzerland, June 30, 2020 /PRNewswire/ -- MedAlliance has announced the award of its second CE Mark: SELUTION SLR 014 PTCA, a novel Sirolimus Drug Eluting Balloon (DEB), for the treatment of coronary arterial disease.
  • Investigators concluded that the data in this study support the safety, efficacy and optimal performance of SELUTION SLR in coronary applications.
  • In February 2020 MedAlliance received CE Mark approval for SELUTION SLR for treatment of peripheral artery disease.
  • Specializes in ground-breaking technology and commercialization of advanced drug device combination products for treatment of coronary and peripheral artery disease.

MedAlliance Gains CE Mark Approval for Coronary SELUTION SLR™ Sirolimus Drug Eluting Balloon

Retrieved on: 
Tuesday, June 30, 2020
Medicine, Interventional cardiology, Medical technology, Clinical medicine, Peripheral artery disease, RTT, Artery disease, Cordis, Drug-eluting stent, Medical devices, Interventional radiology

NYON, Switzerland, June 30, 2020 /PRNewswire/ -- MedAlliance has announced the award of its second CE Mark: SELUTION SLR 014 PTCA, a novel Sirolimus Drug Eluting Balloon (DEB), for the treatment of coronary arterial disease.

Key Points: 
  • NYON, Switzerland, June 30, 2020 /PRNewswire/ -- MedAlliance has announced the award of its second CE Mark: SELUTION SLR 014 PTCA, a novel Sirolimus Drug Eluting Balloon (DEB), for the treatment of coronary arterial disease.
  • Investigators concluded that the data in this study support the safety, efficacy and optimal performance of SELUTION SLR in coronary applications.
  • In February 2020 MedAlliance received CE Mark approval for SELUTION SLR for treatment of peripheral artery disease.
  • Specializes in ground-breaking technology and commercialization of advanced drug device combination products for treatment of coronary and peripheral artery disease.

North America's PTCA Balloon Catheters Market, 2020-2028 Featuring Abbott, B Braun Melsungen, Biotronik, Boston Scientific, Cardinal Health, Cook Medical, and More

Retrieved on: 
Wednesday, June 24, 2020
Catheters, Balloon catheter, Balloon, Cordis

DUBLIN, June 24, 2020 /PRNewswire/ -- The "North America PTCA Balloon Catheters Market 2020-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 24, 2020 /PRNewswire/ -- The "North America PTCA Balloon Catheters Market 2020-2028" report has been added to ResearchAndMarkets.com's offering.
  • The North American PTCA balloon catheters market is expected to grow at a CAGR of 3.25% in the estimated years from 2020 to 2028.
  • Canada's market for PTCA balloon catheters is relatively small when compared to the US.
  • Therefore, the rise in the prevalence of heart-related diseases is propelling the Canadian PTCA balloon catheters market to grow further.

North American PTCA Balloon Catheters Market, Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, June 19, 2020
Medical devices, Health, Catheters, Balloon catheter, Balloon, Cordis

The "North America PTCA Balloon Catheters Market 2020-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America PTCA Balloon Catheters Market 2020-2028" report has been added to ResearchAndMarkets.com's offering.
  • The North American PTCA balloon catheters market is expected to grow at a CAGR of 3.25% in the estimated years from 2020 to 2028.
  • Canada's market for PTCA balloon catheters is relatively small when compared to the US.
  • Therefore, the rise in the prevalence of heart-related diseases is propelling the Canadian PTCA balloon catheters market to grow further.

European Peripheral Vascular Devices Market Report Suite, 2020-2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 29, 2020
Health, Medical devices, Cardiology, Medicine, Medical specialties, Clinical medicine, Atherectomy, Angioplasty, Percutaneous, Stent, Balloon catheter, Embolization, Catheter, Cordis

The "Peripheral Vascular Devices Market Report Suite: Europe 2020-2026 - MedSuite" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Peripheral Vascular Devices Market Report Suite: Europe 2020-2026 - MedSuite" report has been added to ResearchAndMarkets.com's offering.
  • The European peripheral vascular device market was valued at about 1.3 billion in 2019.
  • This is expected to increase over the forecast period at a CAGR of 2.9% to reach about 1.6 billion by 2026.
  • The full report suite on the European market for peripheral vascular (PV) devices includes peripheral arterial stents, peripheral venous stents, percutaneous transluminal angioplasty (PTA) balloon catheters, atherectomy devices, chronic total occlusion (CTO) devices, embolic protection devices (EPDs), stent grafts, surgical grafts, arteriovenous (AV) access thrombectomy devices, inferior vena cava filters, diagnostic and interventional catheters, standard and hydrophilic guidewires, introducer sheaths, vascular closure devices (VCDs) and transcatheter embolization devices.

Merit Medical Receives CE Mark for Wrapsody™ Endovascular Stent Graft System

Retrieved on: 
Tuesday, May 26, 2020
Interventional radiology, Medicine, Stent, Medical specialties, Catheter, Health care, Cordis

(NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, today announced that it received the CE mark for the WRAPSODY Endovascular Stent Graft System from the British Standards Institution (BSI).

Key Points: 
  • (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, today announced that it received the CE mark for the WRAPSODY Endovascular Stent Graft System from the British Standards Institution (BSI).
  • Merit recently completed enrollment and primary follow-up of its WRAPSODY FIRST study which included 46 patients in Europe.
  • Merit intends to systematically introduce the WRAPSODY system in Europe as procedures are resumed following the ongoing lockdown due to COVID-19.
  • The WRAPSODY system is complementary to other products that Merit produces or distributes, such as the HeRO Graft, the Surfacer Inside-Out Access Catheter System and other vascular access products.

Percutaneous Coronary Intervention Industry, 2027: Clinical Trials, Average Pricing, Epidemiology, Opportunities, Roadblocks

Retrieved on: 
Tuesday, May 5, 2020
Percutaneous coronary intervention, Cordis

DUBLIN, May 5, 2020 /PRNewswire/ -- The "Global Percutaneous Coronary Intervention Market Outlook 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, May 5, 2020 /PRNewswire/ -- The "Global Percutaneous Coronary Intervention Market Outlook 2027" report has been added to ResearchAndMarkets.com's offering.
  • The global percutaneous coronary intervention market is anticipated to record a CAGR of 5.39% over the forecast period, i.e.
  • The global percutaneous coronary intervention market consists of various segments that are segmented by product, end users and by region.
  • Based on region, the global percutaneous coronary intervention market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Modern Vascular Among First Medical Facilities in the Country to Perform Post-Angioplasty Dissection Repair Below The Knee with Newly FDA-Approved Tack Endovascular System®

Retrieved on: 
Thursday, April 23, 2020
Medicine, Medical specialties, Clinical medicine, Interventional radiology, Angioplasty, Vascular surgery, Percutaneous, Minimally invasive procedure, Cordis

Todays outpatient procedure was performed by Dr. Scott Brannan, Chief of Endovascular Surgery, at Modern Vasculars clinic in North Mesa, Arizona.

Key Points: 
  • Todays outpatient procedure was performed by Dr. Scott Brannan, Chief of Endovascular Surgery, at Modern Vasculars clinic in North Mesa, Arizona.
  • Dr. Brannan and Modern Vascular have been working with us for almost six months now," says Todd Royal, Territory Director at Intact Vascular.
  • Balloon Angioplasty, also referred to as Percutaneous Transluminal Angioplasty (PTA), is a minimally invasive and effective treatment for PAD and CLI.
  • The Tack Endovascular System is uniquely designed to preserve the vessel, minimize vessel inflammation, and enhance blood flow.

Outlook on the Worldwide Coronary Guidewires Market to 2025 - A Rise in the Number of Interventional Radiology Procedures Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 15, 2020
Radiology, Health, Medicine, Medical specialties, Medical terminology, Minimally invasive procedure, Minimally-invasive surgery, Cardiovascular disease, Surgery, Clinical medicine, Circulatory system, Cordis

According to the World Health Organization (WHO), globally cardiovascular diseases (CVDs) are the number 1 cause of death, an estimated 17.9 million each year suffer from cardiovascular diseases.

Key Points: 
  • According to the World Health Organization (WHO), globally cardiovascular diseases (CVDs) are the number 1 cause of death, an estimated 17.9 million each year suffer from cardiovascular diseases.
  • Increasing prevalence of cardiovascular and renal diseases, rise in a number of interventional diagnostic procedures and growing demand for minimally invasive surgeries are the key driving factors in the stainless steel segment.
  • North America is expected to hold a major market share in the global coronary guidewires market due to increasing prevalence of cardiovascular and renal diseases, rise in number of interventional diagnostic procedures and growing demand for minimally invasive surgeries in this region.
  • Furthermore, favorable reimbursement policies and presence of well-established healthcare infrastructure is fueling the growth of the overall regional market to a large extent.